Akira Yuno

Immunology and Microbiology · Life Sciences

21h-index2.0kcitations107works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(54), vaccines and immunoinformatics approaches(24), Cancer Immunotherapy and Biomarkers(23), CAR-T cell therapy research(23), Cancer Research and Treatments(15)

Publications107 total

Supplementary Figure 2 from Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression
2023Open Access
Supplementary Figure 3 from Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression
2023Open Access
Supplementary igure 1 from Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell Epitopes: KIF20A-Specific CD4<sup>+</sup> T-cell Immunity in Patients with Malignant Tumor
2023Open Access
CCR Translation for This Article from Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell Epitopes: KIF20A-Specific CD4<sup>+</sup> T-cell Immunity in Patients with Malignant Tumor
2023Open Access
Figure S2 from Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
2023Open Access
Supplementary Tables from Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression
2023Open Access
Supplemental Figure 2 from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
2023Open Access
Figure S2 from Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
2023Open Access
Supplementary Figure 2 from Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell Epitopes: KIF20A-Specific CD4<sup>+</sup> T-cell Immunity in Patients with Malignant Tumor
2023Open Access
Supplementary information from Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression
2023Open Access
Data from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
2023Open Access
Supplementary Figure 3 from Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell Epitopes: KIF20A-Specific CD4<sup>+</sup> T-cell Immunity in Patients with Malignant Tumor
2023Open Access
Supplemental Figure 3 from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
2023Open Access
Table S1 from Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
2023Open Access
Supplementary Figure 2 from Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression
2023Open Access
Supplementary Table 2 from Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell Epitopes: KIF20A-Specific CD4<sup>+</sup> T-cell Immunity in Patients with Malignant Tumor
2023Open Access
Supplemental Figure 3 from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
2023Open Access
Supplemental Figure Legends from Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
2023Open Access
Supplementary Text from Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell Epitopes: KIF20A-Specific CD4<sup>+</sup> T-cell Immunity in Patients with Malignant Tumor
2023Open Access
Figure S3 from Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Jane B. Trepel(28), Yasuharu Nishimura(20), Masatoshi Hirayama(18), Yusuke Tomita(17), Min-Jung Lee(16), Satoru Senju(16), Hirotake Tsukamoto(14), Sunmin Lee(13), Yoshihiro Yoshitake(13), Hideki Nakayama(12), Masanori Shinohara(12), Hirofumi Jono(11), Akinobu Hamada(11), Daiki Fukuma(10), Seth M. Steinberg(9), Kenta Kawahara(9), Koji Yoshida(9), Atsushi Irie(9), Takuya Tsunoda(8), William D. Figg(7)